Company Overview
Shree Pacetronix Limited (BSE: 527005, ISIN: INE847D01010) is a listed medical devices company primarily engaged in manufacturing life-saving pacemaker devices. The company operates through its subsidiary Shree Coratomic Limited (99.91% ownership) which handles wholesale trading business.
Financial Performance Highlights
FY26 Consolidated Results:
- Revenue from Operations: ₹2,163.69 crore (29% increase from ₹1,680.32 crore in FY25)
- Net Profit After Tax: ₹314.39 crore (319% surge from ₹74.99 crore in FY25)
- Earnings Per Share (Basic): ₹8.66 (₹2.08 in FY25)
- Effective Tax Rate: 25.39% (28.10% in FY25)
Standalone Performance:
- Revenue: ₹21.64 crore (Previous year: ₹16.80 crore)
- Profit After Tax: ₹3.02 crore (Previous year: ₹0.75 crore)
- EPS (Basic): ₹8.31 (₹2.09 in FY25)
Capital Structure & Fundraising
Share Capital Changes:
- Authorized Capital: ₹5.00 crore (50 lakh equity shares of ₹10 each)
- Paid-up Capital: ₹3.75 crore (37,49,700 equity shares as of March 31, 2026)
- Preferential allotment of 75,150 equity shares at ₹81 per share and 225,450 convertible warrants at ₹81 per warrant to promoters
- 75,150 Series A warrants converted into equity shares on March 20, 2026; 150,300 Series B warrants outstanding
- Total equity raised: ₹15.03 crore from shares + ₹30.44 crore against warrants
Financial Position:
- Total Equity: ₹1,436.05 crore (₹1,018.28 crore in FY25)
- Current Ratio: 2.71 times (1.94 times in FY25)
- Debt-Equity Ratio: 0.02 times (0.03 times in FY25)
- Return on Equity: 19.72% (5.59% in FY25)
Cash Flow Performance
Operating Activities: Net cash inflow of ₹292.25 crore (negative ₹0.79 crore in FY25)
Investing Activities: Net cash outflow of ₹77.70 crore (₹4.13 crore in FY25)
Financing Activities: Net cash outflow of ₹161.03 crore (inflow of ₹18.92 crore in FY25)
Net Cash Increase: ₹53.53 crore (₹14.00 crore in FY25)
Closing Cash Balance: ₹78.95 crore (₹25.42 crore in FY25)
AGM & Corporate Governance
38th Annual General Meeting: September 29, 2026, with 8 resolutions including:
- Adoption of financial statements for FY 2025-2026
- Reappointment of Mr. Akash Sethi as Director and Joint Managing Director
- Appointment of M/s Agarwal Patel and Sinhal as Statutory Auditors for 5 years
- Increase in remuneration of Mr. Akash Sethi to ₹5,00,000 per month
- Approval of related party transactions with Shree Coratomic Limited up to ₹10 crore
Key Management & Board
Executive Directors: Akash Sethi (Joint Managing Director), Atul Kumar Sethi (Managing Director)
Non-Executive Independent Directors: Manali Tongia, Somya Chhabra, Chandragupt Jain
Key Managerial Personnel: Ashok Atulkar (CFO), Rupali Ahire (Company Secretary)
Subsidiary Performance
Shree Coratomic Limited reported turnover of ₹1.75 crore and loss after tax of ₹2.16 lakh. The company seeks approval for material related party transactions with the subsidiary up to ₹10 crore for FY 2026-2027.
Other Disclosures
Employee Strength: 132 permanent employees as of March 31, 2026
Foreign Exchange: Earnings ₹2.58 crore; Outgo ₹2.53 crore
Contingent Liabilities: Bank guarantees ₹54,174.65; GST demand ₹20.00 lakh under dispute
Dividend: No dividend recommended for FY 2025-2026
Corporate Governance: Voluntarily followed despite not being mandatorily required due to size thresholds